Welcome to our dedicated page for Hoth Therapeutics SEC filings (Ticker: HOTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Hoth Therapeutics, Inc. SEC filings document a clinical-stage biopharmaceutical issuer’s material events, capital structure actions, governance arrangements and listing compliance matters. Recent 8-K disclosures cover registered direct offerings of common stock, private-placement warrants, use of a Form S-3 shelf registration, and at-the-market offering prospectus supplements.
The filing record also includes Regulation FD and other-event disclosures for management presentation materials about the therapeutics pipeline and weight-loss drug program, executive employment agreement information, Nasdaq minimum bid price compliance notices, and the formation of Rocket One Inc., a wholly owned subsidiary formed to acquire, own and operate space-industry assets, including nano rocket systems for nanosatellite deployment.
Hoth Therapeutics, Inc. ("HOTH") reported that, on June 18, 2025, The Nasdaq Stock Market notified the company that its common stock satisfied the minimum bid price requirement of $1.00 per share for at least ten consecutive business days, thereby restoring full compliance with Nasdaq Listing Rule 5550(a)(2). The company disclosed the notification in this Form 8-K and simultaneously issued a press release, furnished as Exhibit 99.1.